FEG
CHRS icon

Financial Enhancement Group’s Coherus Oncology CHRS Stock Holding History

Financial Enhancement Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,482
Closed -$26K – 280
2020
Q4 		$26K Buy
+1,482
New +$26.4K 0.01% 165

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Financial Enhancement Group's CHRS Position: Q1 2021 in Review

Financial Enhancement Group sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 1,482 shares — an estimated $26K sold.

Financial Enhancement Group first reported a position in CHRS in Q4 2020 and held it in 1 quarter. The position peaked at $26K in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Financial Enhancement Group reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Financial Enhancement Group sold 1,482 Coherus Oncology shares in Q1 2021, an estimated $26K.
  • Financial Enhancement Group first reported a position in Coherus Oncology in Q4 2020 and held it in 1 quarter.
  • Financial Enhancement Group's Coherus Oncology position peaked at $26K in Q4 2020.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Financial Enhancement Group's 13F filing for Q1 2021, filed 10 May 2021.